Warp Sciences, founded by former OpenAI CPO Kevin Weil to accelerate drug development with AI, emerges from stealth with $215 million funding, valuing it at $865 million
openai
| Source: Techmeme | Original article
Warp Sciences, a stealth AI drug‑development startup founded by former OpenAI CPO Kevin Weil, raised $215 million, valuing the company at $865 million.
Warp Sciences, the AI‑driven drug‑discovery startup founded by former OpenAI chief product officer Kevin Weil, has emerged from stealth with a $215 million financing round that values the company at $865 million post‑money. The round was led by Lightspeed and included participation from IVP, Premji Invest and Lux Capital. Weil, who headed OpenAI’s AI‑for‑science program, co‑founded the venture with data‑science veteran DJ Patil, former Meta super‑intelligence vice‑president Manohar Paluri and entrepreneur Solomon Reisberg.
The capital will be used to build an automated laboratory in the United States for drug‑chemistry work that is currently outsourced to China. By integrating large‑language models and other generative‑AI tools into synthesis planning, analytics and workflow orchestration, Warp Sciences aims to compress the early stages of drug development that traditionally take months or years.
The move signals a growing confidence among venture capitalists that AI can deliver tangible efficiencies in the pharmaceutical pipeline, a sector long dominated by high‑cost, slow‑moving R&D. If successful, the model could lower discovery costs, accelerate timelines for new therapeutics and reshape how biotech firms source chemistry work. It also adds to a wave of AI‑focused spin‑outs from talent that previously built large‑scale models at OpenAI, underscoring the company’s broader influence beyond consumer chat products.
Investors and industry watchers will now monitor Warp Sciences’ progress in establishing its automated lab, the performance of its AI‑driven chemistry platform, and any early partnership announcements with pharmaceutical companies. Demonstrable speed‑ups or cost reductions in real‑world projects could trigger further funding inflows and inspire similar AI‑centric approaches across the life‑science ecosystem.
Sources
Back to AIPULSEN